Phosphomimetic Hsp22 AAV9 Delivery for Tauopathy Memory Deficits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective in treating tauopathies such as Alzheimer's disease, as they fail to address the pathological aggregation of tau protein, leading to cognitive dysfunction and neuronal loss.
Innovation Solution
Administration of a therapeutically effective amount of heat shock protein 22 (Hsp22), specifically a phosphomimetic mutant, to improve cognitive function and synaptic plasticity without altering tau levels or phosphorylation status, using an adeno-associated virus (AAV) vector for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat tauopathies, then treatment is provided, but they fail to address pathological aggregation of tau protein leading to cognitive dysfunction
Solution Approach 1:
The patent introduces molecular chaperones (Hsp27, Hsp22) as intermediary proteins that bind to tau protein and prevent its pathological aggregation. These chaperones act as mediators between the cellular environment and tau protein, facilitating proper folding and preventing formation of toxic aggregates that cause cognitive dysfunction in tauopathies like Alzheimer's disease.
Solution Approach 2:
The patent employs phosphomimetic mutants of Hsp22 (S24D, S57D) where specific serine residues are replaced with aspartic acid to mimic the negatively charged state of phosphorylated serine. This parameter change in the chaperone protein's charge distribution enhances its ability to bind and stabilize tau protein, improving its protective effect against aggregation without requiring actual phosphorylation events.
2Object-affected harmful factors
If molecular chaperones are used to regulate tau accumulation, then neuronal damage is reduced, but the mechanism requires understanding of complex protein interactions
Solution Approach 1:
The patent extracts and isolates the essential protective function of molecular chaperones from the complex cellular environment. By identifying and expressing specific chaperone proteins (Hsp27, Hsp22) and their phosphomimetic mutants, the invention simplifies the complex network of protein-protein interactions into a targeted therapeutic approach where a single overexpressed chaperone protein can protect neurons from tau-mediated damage without requiring complete understanding or manipulation of the entire chaperone system.
3Ease of operation
If Hsp22 phosphomimetic mutant is administered, then cognitive function and synaptic plasticity are improved, but delivery to brain requires viral vector system
Solution Approach 1:
The patent uses adeno-associated virus (AAV) vectors as intermediary delivery vehicles to transport the Hsp22 phosphomimetic mutant gene into brain cells. The viral vector acts as a mediator that facilitates gene delivery across the blood-brain barrier and into neuronal cells, enabling sustained expression of the protective chaperone protein in the brain without requiring direct administration of the protein itself, which would have limited penetration and short half-life.
Data Source
AI summary
A method of improving cognition, learning and memory in a patient having a tauopathy neurodegenerative disease by the administration of small heat shock protein 22 (Hsp22) is presented. Administration of both wild type Hsp22 and a mutant phosphomimetic Hsp22 were found to increase synaptic plasticity and long term potentiation thus leading to increases in cognition, learning and memory in patients having a tauopathy such as Alzheimer's disease. These increases were found to be independent of tau accumulation and phosphorylation in vivo.